Andrew William Dowsey

Prof. Andrew William Dowsey

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Communications Biology
Verified
Journal Article
Open access
PDF file
JXJingshu Xu
Jingshu Xu
SPStefano Patassini
Stefano Patassini
NRNitin Rustogi
Nitin Rustogi
IRIsabel Riba-Garcia
Isabel Riba-Garcia
BHBenjamin D. Hale
Benjamin D. Hale
RURichard Unwin
Richard Unwin
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently affects 36 million people worldwide with no effective treatment available. Development of AD follows a distinctive pattern in the brain and is poorly modelled in animals. Therefore, it is vital to widen the spatial scope of the study of AD and prioritise the study of human brains. Here we show that functionally distinct human brain regions display varying and region-specific changes in protein expression. These changes provide insights into the progression of disease, novel AD-related pathways, the presence of a gradient of protein expression change from less to more affected regions and a possibly protective protein expression profile in the cerebellum. This spatial proteomics analysis provides a framework which can underpin current research and open new avenues to enhance molecular understanding of AD pathophysiology, provide new targets for intervention and broaden the conceptual frameworks for future AD research.

12 August 2003 in Proteomics
Verified
Journal Article
Closed access
PDF file
ADAndrew William Dowsey
Andrew William Dowsey
MDMichael J. Dunn
Michael J. Dunn
GYGuang‐Zhong Yang
Guang‐Zhong Yang

27 February 2009 in Communications in Numerical Methods in Engineering
Verified
Journal Article
Closed access
PDF file
RTRyo Torii
Ryo Torii
NWNigel B. Wood
Nigel B. Wood
NHNearchos Hadjiloizou
Nearchos Hadjiloizou
ADAndrew William Dowsey
Andrew William Dowsey
AWAndrew R. Wright
Andrew R. Wright
XXX. Yun Xu
X. Yun Xu

15 October 2015 in Diabetes
Verified
Journal Article
Open access
PDF file
OFOliver J. Freeman
Oliver J. Freeman
RURichard Unwin
Richard Unwin
ADAndrew William Dowsey
Andrew William Dowsey
PBPaul Begley
Paul Begley
SASumia Ali
Sumia Ali
NGNatalie J. Gardiner
Natalie J. Gardiner
High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However, our understanding of the molecular mechanisms that cause the marked distal pathology is incomplete. We performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN. We integrated proteomics and metabolomics from the sciatic nerve (SN), the lumbar 4/5 dorsal root ganglia (DRG), and the trigeminal ganglia (TG) of streptozotocin-diabetic and healthy control rats. Even though all tissues showed a dramatic increase in glucose and polyol pathway intermediates in diabetes, a striking upregulation of mitochondrial oxidative phosphorylation and perturbation of lipid metabolism was found in the distal SN that was not present in the corresponding cell bodies of the DRG or the cranial TG. This finding suggests that the most severe molecular consequences of diabetes in the nervous system present in the SN, the region most affected by neuropathy. Such spatial metabolic dysfunction suggests a failure of energy homeostasis and/or oxidative stress, specifically in the distal axon/Schwann cell–rich SN. These data provide a detailed molecular description of the distinct compartmental effects of diabetes on the PNS that could underlie the distal-proximal distribution of pathology.

9 June 2016 in Scientific Reports
Verified
Journal Article
Open access
JXJingshu Xu
Jingshu Xu
PBPaul Begley
Paul Begley
SCStephanie J. Church
Stephanie J. Church
SPStefano Patassini
Stefano Patassini
SMSelina McHarg
Selina McHarg
GCGarth J. S. Cooper
Garth J. S. Cooper
Impairment of brain-glucose uptake and brain-copper regulation occurs in Alzheimer’s disease (AD). Here we sought to further elucidate the processes that cause neurodegeneration in AD by measuring levels of metabolites and metals in brain regions that undergo different degrees of damage. We employed mass spectrometry (MS) to measure metabolites and metals in seven post-mortem brain regions of nine AD patients and nine controls, and plasma-glucose and plasma-copper levels in an ante-mortem case-control study. Glucose, sorbitol and fructose were markedly elevated in all AD brain regions, whereas copper was correspondingly deficient throughout (all P < 0.0001). In the ante-mortem case-control study, by contrast, plasma-glucose and plasma-copper levels did not differ between patients and controls. There were pervasive defects in regulation of glucose and copper in AD brain but no evidence for corresponding systemic abnormalities in plasma. Elevation of brain glucose and deficient brain copper potentially contribute to the pathogenesis of neurodegeneration in AD.

1 August 2014 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
TKTiarnan D. L. Keenan
Tiarnan D. L. Keenan
CPClaire E. Pickford
Claire E. Pickford
RHRebecca J. Holley
Rebecca J. Holley
SCSimon John Clark
Simon John Clark
WLWanchang Lin
Wanchang Lin
PBPaul Bishop
Paul Bishop
Purpose. Heparan sulfate (HS) has been implicated in age-related macular degeneration (AMD), since it is the major binding partner for complement factor H (CFH) in human Bruch's membrane (BrM), and CFH has a central role in inhibiting complement activation on extracellular matrices. The aim was to investigate potential aging changes in HS quantity and composition in human BrM. Methods. Postmortem human ocular tissue was obtained from donors without known retinal disease. The HS was purified from BrM and neurosensory retina, and after digestion to disaccharides, fluorescently labeled and analyzed by reverse-phase HPLC. The HS and heparanase-1 were detected by immunohistochemistry in macular tissue sections from young and old donors, and binding of exogenously applied recombinant CCP6-8 region of CFH (402Y and 402H variants) was compared. Results. Disaccharide analysis demonstrated that the mean quantity of HS in BrM was 50% lower (P = 0.006) in old versus young donors (average 82 vs. 32 years). In addition, there was a small, but significant decrease in HS sulfation in old BrM. Immunohistochemistry revealed approximately 50% (P = 0.02) less HS in macular BrM in old versus young donors, whereas heparanase-1 increased by 24% in old macular BrM (P = 0.56). In young donor tissue the AMD-associated 402H CCP6-8 bound relatively poorly to BrM, compared to the 402Y form. In BrM from old donors, this difference was significantly greater (P = 0.019). Conclusions. The quantity of HS decreases substantially with age in human BrM, resulting in fewer binding sites for CFH and especially affecting the ability of the 402H variant of CFH to bind BrM.